Medusa™ is a hydrogel depot technology that allows an improved delivery, thus resulting in stronger treatment adherence. This innovative approach enables the modified and controlled delivery of drug between one day and one week of drugs without altering the underlying compound. Medusa™ is particularly suited to the development of subcutaneously administered drug formulations.
- Medusa™ has the potential to provide:
- Improved dosing for biologic drugs with established markets
- Product differentiation e.g. improvement of pharmacokinetic (and potentially pharmacodynamics) parameters
- Protection of market position through product differentiation and/or patent extension
Avadel is actively seeking partnership opportunities for Medusa™.
Please contact our business development team for more information.